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CURRENT OUTCOMES OF REDUCED-INTENSITY CONDITIONING ALLO-
GENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS
WITH SAP DEFICIENCY AND XIAP DEFICIENCY
Marsh, R.A., Bleesing, J.J., Jordan, M.B., Davies, S.M., Filipovich, A.H.
Cincinnati Children’s Hospital, Cincinnati, OH
Deficiencies of SAP and XIAP are both associated with X-linked
lymphoproliferative disease (XLP) and are treated with allogeneic
hematopoietic cell transplantation (HCT). At the current time, there
is a paucity of literature concerning the use of RIC HCT for these
patients. Fourteen patients with SAP (n 5 9) and XIAP (n 5 5) de-
ficiencies have been treated at Cincinnati Children’s Hospital using
a RIC regimen consisting of fludarabine (150mg/M2 if weight .
10kg, or 5mg/kg if weight\10kg), melphalan (140mg/M2 if weight
. 10kg, or 4.7mg/kg if weight\ 10kg), and alemtuzumab (median
dose of 1 mg/kg given over days -22 to -19, -12 to -9, -11 to -8, -9
to -5, or on days -23, -12, -11). All but one pateint received methyl-
prednisolone plus cyclosporine or tacrolimus for graft versus host
disease (GVHD) prophylaxis. All patients received anti-microbial
prophylaxis. Patients received 6/8, 7/8, or 8/8 HLA mismatched or
matched bone marrow grafts. Median time to neutrophil recovery
was 10.5 days (range 8-20). There were no transplant-related toxic-
ities, and no cases of grades II-IV acuteGVHD.Mixed chimerism (\
95% donor cells in peripheral blood) developed in 7/14 patients at
a median of 48 days (range 17-118) following HCT. Three of these
patients maintained greater than 50% donor chimerism without in-
tervention. Stem cell boost and/or donor lymphocyte infusions
(DLI) were utilized in 4 patients, which resulted in stable donor con-
tribution to hematopoiesis of greater than 50%. One patient devel-
oped grade II acute GVHD related to DLI. Infectious
complications included EBV viremia in 1 patient, CMV viremia in
3 patients, and adenovirus viremia in 7 patients. A lower extremity
cellulitis and abscess developed in 1 patient, who later developed var-
icella. Significant pneumonia developed in 4 patients. One patient
experienced a constellation of complications including BK viruria,
adenovirus infection, diffuse alveolar hemorrhage, multiple central
nervous system infections, Klebsiella pneumoniae pneumonia, and re-
nal failure. Nine of 14 patients are currently surviving at a median
follow-up of 907 days post-HCT. Four deaths were the result of in-
fectious complications related to the transplant. The fifth death was
the result of complications of multivisceral transplant. All survivors
have a Lansky score of 100. We conclude that RIC-HCT is a viable
option for patients with SAP and XIAP deficiencies.408
MAXIMALLY TOLERATED BUSULFAN AREA UNDER THE CONCENTRA-
TION-TIME CURVE (AUC) IN COMBINATION WITH FLUDARABINE AS
CONDITIONING PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION
Perkins, J.1, Fields, T.1, Kim, J.2, Fernandez, H.1, Perez, L.1, Ayala, E.1,
Kharfan-Dabaja, M.1, Tomblyn, M.1, Sullivan, D.1, Anasetti, C.1 1H.
Lee Moffitt Cancer Center, Tampa, FL; 2H. Lee Moffitt Cancer Center,
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Intravenous busulfan (IV Bu) dosing in hematopoietic cell trans-
plantation (HCT) has been based largely on bioequivalence studies
done with the oral dosage form. As systemic exposure to Bu has
been correlated with efficacy and toxicity, we used area under the
concentration-time curve (AUC) to prospectively determine the
maximally tolerated systemic exposure to IV Bu when given daily
in combination with fludarabine. 3 AUC levels were planned:
6000, 7500, and 9000 micromole*min/L, in cohorts of 20 patients
(pts) each, with an additional 10 pts to be enrolled at the maximally
tolerated AUC. Pts had be 16-65 years old and have a hematologic
malignancy, an HLAA, B, C, DRB1 8/8 or 7/8 matched donor, Kar-
nofsky performance status 70-100%, and adequate organ function.
The initial dose of IV Bu was 170mg/m2/day on day -6 and day -5;
day -4 and day -3 doses were adjusted based on pharmacokinetic
modeling after the first dose to achieve an average daily AUC of
6000. First doses for the subsequent cohorts were based on the linear
correlation between AUC and dose in the previous cohort: 180mg/
m2/day for AUC 7500 and 220mg/m2/day for AUC 9000, withdose adjustment on days -4 and -3 as described. Pharmacokinetic
analysis was done after the last dose to verify the accuracy of the
dose adjustments. The first 20 pts in the AUC 6000 cohort (DL1)
were coenrolled onto a randomized trial of GVHD prophylaxis
and were analyzed separately from a second cohort of 20 pts receiv-
ing AUC 6000 (DL1A) and standard prophylaxis. 20 pts were then
enrolled onto AUC 7500 (DL2), followed by 3 pts on AUC 9000
(DL3). All DL3 pts had dose limiting toxicity so accrual to that level
was stopped. An additional 9 pts have been treated on DL2; 2 are\
100 days posttransplant and are not evaluable for toxicity or GVHD.
The dose-limiting toxicity seen at DL3 was hepatic venoocclusive
disease (VOD) which developed in all 3 pts; 2 pts died. There was
no difference between the dose levels in cumulative incidence of re-
lapse (p5 0.58) or event-free survival (p5 0.5). Nonrelapse mortal-
ity at 6 months was significantly different: DL1 20%, DL1A 0%,
DL2 18.8% and DL3 67% (p 5 0.02). Overall survival at 6 months
was DL1 75%, DL1A 90%, DL2 78%, and DL3 33% (p 5 0.06).
We conclude that 7500 micromole*min/L is the maximally tolerated
AUC based on protocol-defined criteria but exceeding an AUC of
6000 may not provide any benefit due to the increase in nonrelapse
mortality.409
FEATURES OF FRAILTY ARE SURPRISINGLY COMMON IN ADULTS 50
YEARS AND OLDER UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) IN THE MODERN ERA
Artz, A.1, Swanson, K.1, Kocherginsky, M.2, Godley, L.1,-, Kline, J.1,
Nguyen, V.1, Odenike, T.1, Stock,W.1, Larson, R.1, van Besien, K.1 1Uni-
versity of Chicago, Chicago, IL; 2University of Chicago, Chicago, IL;
3Northwestern University School of Medicine, Chicago, IL
Introduction: The rapid growth in HCT for adults 50 years and
older demands better measures of age related impairments to deter-
mine eligibility and tolerance.
Methods:We performed a prospective comprehensive geriatric as-
sessment (CGA) incorporating measures of frailty before HCT for
consecutive adults 50 years and older between 2005 and 2010. All
diseases and conditioning regimens were acceptable. To assess
frailty, we employed the 5 point Fried criteria. This includes three
self-report domains of unintentional weight loss, feeling of exhaus-
tion and low physical activity and two performance based measures
of walking speed and hand-grip strength. A score of 0 is normal; 1-
2 and 3-5 reflect pre-frail and frail, respectively.
Results: Among 146 pts who underwent CGA, 95 had complete
frailty data in all 5 domains. Missing information arose from incom-
plete questionnaires and/or performance based tests. Among the 95
with complete frailty data, scores of 0 and 1 were found in 18.9% and
31.6%, respectively. Another 24.2% had 2 features of frailty and
25.2% met full frailty criteria (i.e., 3 or more). Higher frailty scores
showed no association with greater comorbidity by HCT-CI (P 5
.3). Age did not impact frailty; two or more frailty features occurred
in 45% of those 60 and older and 54% for those 50-59 years (P 5
.82). However, more frailty domains were strongly associated with
active disease at HCT (P 5 .008) and worse performance status (P
5 .004). Pts exhibiting 2 or more frailty domains demonstrated
higher day 180 cumulative incidence of relapse at 27% compared
to only 4.5% for less frail patients (P 5 .014). When restricting
the analysis to pts in partial or complete remission, similar but
non-significant relapse differences were found of 19% for 2 or
more frailty features versus 3.5% without (P 5 .22). Higher frailty
scores had no impact on non-relapse mortality, acute GVHD (P 5
.23) or overall survival (P 5 .32)
Conclusion:We demonstrate for the first time the high prevalence
of a frailty phenotype in older adults immediately prior to HCTwith
81% meeting at least pre-frail criteria and 24% being frail. The as-
sociation of frailty with advanced pre-HCT disease and relapse but
not greater age intimates prior treatment before HCT conditioning
results in a significant loss of reserve and a phenotype of accelerated
aging. These data suggest the traditional notion that older patients
undergoing HCT are selected for robust health, at least in the
modern era of reduced intensity conditioning, may be spurious.
